Ignyta Inc. buy tamam
Zusammenfassung
Diese Einschätzung wurde am 22.12.17 mit einem Endkurs von 24,17 € beendet. Satte Gewinne von 66,46 % verzeichnete die BUY Einschätzung von tamam. tamam hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Ignyta Inc. | - | - | - | - |
| iShares Core DAX® | 0,60 % | 3,08 % | 16,09 % | 16,44 % |
| iShares Nasdaq 100 | 0,90 % | 5,34 % | 29,24 % | 56,43 % |
| iShares Nikkei 225® | 1,78 % | -1,21 % | 6,82 % | 4,77 % |
| iShares S&P 500 | 0,99 % | 3,50 % | 24,96 % | 47,18 % |
Kommentare von tamam zu dieser Einschätzung
In der Diskussion Ignyta Inc. diskutieren
Ignyta keeps soaring...
Ignyta is up on the heels of its announcement that the European Medicines Agency (EMA) has designated Entrectinib (lung cancer candidate) a Priority Medicine (PRIME) for the treatment of NTRK-positive, locally advanced/metastatic solid tumors in adult and pediatric patients who have either progressed following prior therapies or who have no acceptable therapeutic options.
PRIME status provides for enhanced EMA support and accelerated review of the marketing application. It is akin to the FDA's Breakthrough Therapy designation.
Entrectinib, a selective tyrosine kinase inhibitor, is being developed for the treatment of a variety of tumor types. Tyrosine kinase is an enzyme that serves as an "on/off" switch in many cellular functions. If stuck "on" unregulated cell growth occurs.
The company's CEO: “Based on these data, we believe that entrectinib has the potential to be a best-in-class therapeutic option as a first-line targeted therapy for patients with ROS1-positive NSCLC. The extended duration of response and progression free survival times observed in these interim data are particularly compelling, and we believe may be driven by entrectinib’s CNS activity. Entrectinib is designed to cross the blood-brain barrier, allowing it to both address preexisting CNS lesions and have the potential to prevent or delay the onset of metastases to the brain, a common site of progression, particularly in NSCLC"
Not surprisingly, analysts are climbing on the Ignyta bandwagon. Both Cantor Fitzgerald ($23 price target, up from $15 previously) and Ladenburg ($31 price target, up from $20 previously) reiterated Buy ratings after updated data was presented.
Ladenburg's analyst upped his view on the Entrectinib's expected market share in 2022 from 46.5 percent to 56.8 percent and this compound's revenue is now modeled to be $907 million, up from his prior estimate of $574 million.
That said, longer term the stock could well have additional significant upside over the long term. Note: Just as I about to hit submit, it appears a secondary offering is in the works.